Sintilimab plus oxaliplatin and capecitabine versus sintilimab plus albumin-bound paclitaxel and capecitabine for advanced unresectable gastric and gastroesophageal junction (GEJ) adenocarcinoma patients: A prospective, randomized, open-label, investigator-initiated phase 2 trial.

作者
Kai Chen,Wei Li,Caihua Xu,Qing Guo,Dapeng Li,Lian Lian,Xiumin Zhou,Yulan Gu,Wei Fu,Weiming Duan,Rong Wang,Yonghua Zhang
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:43 (16_suppl)
标识
DOI:10.1200/jco.2025.43.16_suppl.e16042
摘要

e16042 Background: The treatment options for locally advanced unresectable GEJ adenocarcinoma are still limited in China. Sintilimab is a PD1 mAb, previous ORIENT-16 study has demonstrated its combination with XELOX regimen had improved OS and tolerable toxicity in first line GEJ carcinoma treatment. Nanoparticle albumin-bound paclitaxel is a form of paclitaxel that does not require steroid premedication to prevent hypersensitivity reactions, which may bring more benefits for this cohort of patients. Methods: Patients with pathologically confirmed advanced unresectable GEJ adenocarcinoma were enrolled and randomly assigned to arm A: sintilimab 200mg, IV, D1, Q3W; capecitabine 1000 mg/m 2 , PO, BID, D1-14, Q3W; oxaliplatin 130 mg/m 2 , IV, Q3W; and arm B: albumin-bound paclitaxel 260 mg/m 2 , IV, D1, Q3W, sintilimab and capecitabine dose were the same with arm A. The primary endpoints were ORR and PFS per RECIST 1.1. Results: As of 28 th Dec 2024, 39 patients were enrolled, 23 from arm A and 16 from arm B. In these 2 arms, median age were 69 and 70, male patients accounted for 60.9% and 87.5%, respectively; in arm A, 78.3% subjects had ECOG score 0, 21.7% had score 1, in arm B, they were both 50%; 8.7% subjects in arm A had > = 3 metastatic sites, and that in arm B was 6.3%. 23 arm A and 16 arm B patients were analyzed for safety profile, 39.1% of patients in arm A had any grade treatment-emergent adverse events (TEAEs), the most common (> 10%) was anemia (21.7%),; 43.8% in arm B had any-grade TEAEs, with the most common being hepatic failure (12.5%). 17.4% of patients in arm A had dose interruption/delay, and 17.4% had dose reduction, those in arm B were 18.8% and 0. Immune-related AEs occurred in 4.3% of patients in arm A (hepatic failure) and none in arm B. Efficacy was analyed in 20 patients from arm A and 16 from arm B, the confirmed ORR was 35.0% (7/20, 95% CI 15.4%- 59.2%) and 37.5% (6/16, 95% CI 15.2%- 64.6%), respectively. Disease control rate (DCR) was 85.0% (17/20, 95% CI 62.1%-96.8%) and 93.8% (15/16, 95% CI 69.8%-99.8%), respectively, and the median PFS was 6.74 months (95% CI 4.73-Not reached) in arm A and 7.23 months (95% CI 7.23-Not reached) in arm B. Conclusions: Sintilimab in combination with albumin-bound paclitaxel and capecitabine showed similar efficacy with sintilimab plus XELOX, with tolerable toxicity, however, due to limited sample size and follow-up time, it’s hard to draw any solid conclusions, we will continue to observe the safety and efficacy of this regimen in locally advanced unresectable gastric and gastroesophageal adenocarcinoma patients. Clinical trial information: ChiCTR2300077373 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
万能图书馆的应助被loudei采纳,获得10
刚刚
隐形曼青的应助被翻车鱼采纳,获得10
刚刚
予秋发布了新的文献求助10
刚刚
111完成签到 ,获得积分10
刚刚
刚刚
可爱的函函的应助被jiangsuway采纳,获得10
1秒前
我是老大的应助被透射电镜采纳,获得10
1秒前
重要莹发布了新的文献求助10
1秒前
123的应助被羊羊羊采纳,获得10
1秒前
一棵草完成签到,获得积分10
1秒前
未了完成签到,获得积分10
2秒前
duke发布了新的文献求助10
2秒前
ow完成签到,获得积分10
2秒前
winnie你外卖到了完成签到,获得积分10
2秒前
阿飞发布了新的文献求助10
2秒前
董家旭发布了新的文献求助10
2秒前
赛赛完成签到 ,获得积分10
3秒前
追寻的雅柔完成签到,获得积分10
3秒前
调皮冰蝶发布了新的文献求助20
3秒前
3秒前
于际泽完成签到,获得积分10
3秒前
思策发布了新的文献求助10
3秒前
小高今天努力了么的应助被jin采纳,获得10
3秒前
辛z发布了新的文献求助20
4秒前
彤航完成签到,获得积分10
4秒前
玲玲发布了新的文献求助10
4秒前
高高完成签到,获得积分10
4秒前
NumbCn完成签到,获得积分10
5秒前
virbaroque完成签到,获得积分10
5秒前
郑敏阳完成签到,获得积分10
5秒前
无极微光的应助被千日粉采纳,获得20
5秒前
憨豆完成签到 ,获得积分10
6秒前
zz发布了新的文献求助10
7秒前
柠柠完成签到,获得积分10
7秒前
8秒前
8秒前
8秒前
8秒前
wl完成签到,获得积分10
8秒前
wxyZ发布了新的文献求助10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180586
求助须知:如何正确求助?哪些是违规求助? 9570581
关于积分的说明 21813457
捐赠科研通 7776777
什么是DOI,文献DOI怎么找? 3433294
关于科研通互助平台的介绍 2557547
邀请新用户注册赠送积分活动 2479253